{"id":"NCT01478347","sponsor":"Novartis Vaccines","briefTitle":"A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults","officialTitle":"A Phase 3b, Single-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05","primaryCompletion":"2014-03","completion":"2014-11","firstPosted":"2011-11-23","resultsPosted":"2015-03-06","lastUpdate":"2015-03-27"},"enrollment":18,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Disease","Meningococcal Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"Recombinant meningococcal B + OMV NZ","otherNames":[]}],"arms":[{"label":"rMenB+OMV NZ","type":"EXPERIMENTAL"}],"summary":"The proposed study will evaluate the safety of the rMenB+OMV NZ in an adult population potentially at risk for meningococcal disease (e.g. lab workers).\n\nIn the second part of the study additional blood samples of high responding vaccinated subjects will be collected for the purpose of generating a control serum panel for the human serum bactericidal assay (hSBA) tests.","primaryOutcome":{"measure":"Number of Subjects Reporting Unsolicited Adverse Events, Following Vaccination With Two Injections of rMenB+OMV NZ Vaccine Between Day 1 Through Day 91.","timeFrame":"Day 1 to day 91","effectByArm":[{"arm":"rMenB+OMV NZ","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Pharyngitis","Urinary tract infection"]}}